113 related articles for article (PubMed ID: 25423960)
1. HPV Status Determines the Efficacy of Adjuvant Chemotherapy With S-1, an Oral Fluorouracil Prodrug, in Oropharyngeal Cancer.
Wakisaka N; Yoshida S; Kondo S; Kita M; Endo K; Tsuji A; Murono S; Muramatsu M; Yoshizaki T
Ann Otol Rhinol Laryngol; 2015 May; 124(5):400-6. PubMed ID: 25423960
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
[TBL] [Abstract][Full Text] [Related]
3. Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer.
Hasegawa H; Fujitani K; Kurokawa Y; Hirao M; Nakazuru S; Mita E; Tsujinaka T
Chemotherapy; 2010; 56(6):436-43. PubMed ID: 21088394
[TBL] [Abstract][Full Text] [Related]
4. Human papilloma virus in locally advanced stage III/IV squamous cell cancer of the oropharynx and impact on choice of therapy.
Ihloff AS; Petersen C; Hoffmann M; Knecht R; Tribius S
Oral Oncol; 2010 Oct; 46(10):705-11. PubMed ID: 20843732
[TBL] [Abstract][Full Text] [Related]
5. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
Namikawa T; Munekage E; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Anticancer Res; 2014 Dec; 34(12):7297-301. PubMed ID: 25503163
[TBL] [Abstract][Full Text] [Related]
6. High-risk HPV and survival in patients with oral and oropharyngeal squamous cell carcinoma - 5-year follow up of a population-based study.
Annertz K; Rosenquist K; Andersson G; Jacobsson H; Hansson BG; Wennerberg J
Acta Otolaryngol; 2014 Aug; 134(8):843-51. PubMed ID: 24930912
[TBL] [Abstract][Full Text] [Related]
7. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
Cao S; Lu K; Tóth K; Slocum HK; Shirasaka T; Rustum YM
Clin Cancer Res; 1999 Feb; 5(2):267-74. PubMed ID: 10037174
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
10. [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
Sakurai Y; Kamoshida S; Furuta S; Sunagawa R; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1147-55. PubMed ID: 18633253
[TBL] [Abstract][Full Text] [Related]
11. Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV status.
Kim MJ; Ki MS; Kim K; Shim HJ; Hwang JE; Bae WK; Chung IJ; Lee DH; Lee JK; Yoon TM; Lim SC; Chung WK; Jeong JU; Lim HS; Choi YD; Cho SH
BMC Cancer; 2014 Nov; 14():824. PubMed ID: 25380690
[TBL] [Abstract][Full Text] [Related]
12. S-1 for advanced colorectal cancer: do we need another oral fluorouracil prodrug?
Schmoll HJ
Lancet Oncol; 2010 Sep; 11(9):808-9. PubMed ID: 20816370
[No Abstract] [Full Text] [Related]
13. Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer.
Tsukuda M; Kida A; Fujii M; Kono N; Yoshihara T; Hasegawa Y; Sugita M;
Br J Cancer; 2005 Oct; 93(8):884-9. PubMed ID: 16189518
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
Ohtsu A; Baba H; Sakata Y; Mitachi Y; Horikoshi N; Sugimachi K; Taguchi T
Br J Cancer; 2000 Jul; 83(2):141-5. PubMed ID: 10901361
[TBL] [Abstract][Full Text] [Related]
15. [A case of advanced lateral wall oropharyngeal carcinoma showing complete response to chemotherapy with TS-1].
Iguchi H; Hashimoto K; Sunami K; Takayama M; Nakamura A; Yamane H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):101-4. PubMed ID: 12557712
[TBL] [Abstract][Full Text] [Related]
16. Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
Omura T; Shimada Y; Nagata T; Okumura T; Fukuoka J; Yamagishi F; Tajika S; Nakajima S; Kawabe A; Tsukada K
Oncol Rep; 2014 Feb; 31(2):613-8. PubMed ID: 24317477
[TBL] [Abstract][Full Text] [Related]
17. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.
O'Sullivan B; Huang SH; Siu LL; Waldron J; Zhao H; Perez-Ordonez B; Weinreb I; Kim J; Ringash J; Bayley A; Dawson LA; Hope A; Cho J; Irish J; Gilbert R; Gullane P; Hui A; Liu FF; Chen E; Xu W
J Clin Oncol; 2013 Feb; 31(5):543-50. PubMed ID: 23295795
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
[TBL] [Abstract][Full Text] [Related]
19. [A randomized controlled trial to evaluate the effect of adjuvant oral fluoropyrimidine derivative therapy after curative resection for stage II/III rectal cancer-adjuvant chemotherapy trial of S-1 for rectal cancer (ACTS-RC):].
Oki E; Kakeji Y; Yoshida R; Ikeda K; Nishida K; Koga T; Egashira A; Tokunaga E; Morita M; Baba H; Maehara Y
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():138-43. PubMed ID: 16897990
[TBL] [Abstract][Full Text] [Related]
20. [Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].
Takebayashi K; Kawai Y; Tagi T; Matsumura M; Shimizu K; Yamamoto H; Mekata E; Tani T; Sato M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):385-7. PubMed ID: 22421764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
